Francois Bertucci

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi request reprint Identification and validation of an ERBB2 gene expression signature in breast cancers
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR119 Inserm, IFR57, and Faculté de Médecine, Universite de la Mediterranee, Marseille, France
    Oncogene 23:2564-75. 2004
  2. pmc Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer
    Renaud Sabatier
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 INSERM and Institut Paoli Calmettes Marseille, Marseille, France
    PLoS ONE 6:e27656. 2011
  3. pmc High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes
    Ismahane Bekhouche
    Marseille Cancer Research Center CRCM, UMR891 Inserm, Institut Paoli Calmettes, Department of Molecular Oncology, Marseille, France
    PLoS ONE 6:e16950. 2011
  4. pmc Solitary fibrous tumor in the round ligament of the liver: a fortunate intraoperative discovery
    Laura Beyer
    Department of Surgical Oncology, Institut Paoli Calmettes, Marseille, France
    Case Rep Oncol 5:187-94. 2012
  5. pmc Solitary fibrous tumor of the prostate: case report and review of the literature
    Laurence Moureau-Zabotto
    Department of Radiotherapy, University of Mediterranea, Marseille, Montreal, Que, Canada
    Case Rep Oncol 5:22-9. 2012
  6. pmc A seven-gene prognostic model for platinum-treated ovarian carcinomas
    R Sabatier
    Department of Molecular Oncology, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, 13009 Marseille, France
    Br J Cancer 105:304-11. 2011
  7. doi request reprint [Genomics and clinical research for breast cancer]
    Francois Bertucci
    Departement d Oncologie Medicale, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, France
    Med Sci (Paris) 28:14-8. 2012
  8. pmc Feature extraction and signal processing for nylon DNA microarrays
    F Lopez
    TAGC, INSERM ERM 206, Parc Scientifique de Luminy, 13288 Marseille, France
    BMC Genomics 5:38. 2004
  9. pmc Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Aurore Blesius
    Department of Medicine, Institut Roussy, Villejuif, France
    BMC Cancer 11:72. 2011
  10. doi request reprint How different are luminal A and basal breast cancers?
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Marseille, France
    Int J Cancer 124:1338-48. 2009

Detail Information

Publications120 found, 100 shown here

  1. ncbi request reprint Identification and validation of an ERBB2 gene expression signature in breast cancers
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR119 Inserm, IFR57, and Faculté de Médecine, Universite de la Mediterranee, Marseille, France
    Oncogene 23:2564-75. 2004
    ..Some correlations were validated at the protein level using IHC on tissue microarrays. The GES was able to distinguish ERBB2-negative and -positive cancer samples, as well as FISH-negative and FISH-positive ERBB2 2+ IHC samples...
  2. pmc Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer
    Renaud Sabatier
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 INSERM and Institut Paoli Calmettes Marseille, Marseille, France
    PLoS ONE 6:e27656. 2011
    ..ECRG4/C2ORF40 is a potential tumor suppressor gene (TSG) recently identified in esophageal carcinoma. Its expression, gene copy number and prognostic value have never been explored in breast cancer...
  3. pmc High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes
    Ismahane Bekhouche
    Marseille Cancer Research Center CRCM, UMR891 Inserm, Institut Paoli Calmettes, Department of Molecular Oncology, Marseille, France
    PLoS ONE 6:e16950. 2011
    ..Inflammatory breast cancer (IBC) is an aggressive form of BC poorly defined at the molecular level. We compared the molecular portraits of 63 IBC and 134 non-IBC (nIBC) clinical samples...
  4. pmc Solitary fibrous tumor in the round ligament of the liver: a fortunate intraoperative discovery
    Laura Beyer
    Department of Surgical Oncology, Institut Paoli Calmettes, Marseille, France
    Case Rep Oncol 5:187-94. 2012
    ..It illustrates the difficulty in diagnosing such tumors. Whilst diagnosis of SFT is rare, it should be kept in mind to allow early diagnosis and complete surgical resection, which provide the best chance for recovery...
  5. pmc Solitary fibrous tumor of the prostate: case report and review of the literature
    Laurence Moureau-Zabotto
    Department of Radiotherapy, University of Mediterranea, Marseille, Montreal, Que, Canada
    Case Rep Oncol 5:22-9. 2012
    ..In conclusion, we report a new exceptional case of prostatic SFT. We review the literature and discuss the challenging issues of misdiagnosis, prognosis and treatment...
  6. pmc A seven-gene prognostic model for platinum-treated ovarian carcinomas
    R Sabatier
    Department of Molecular Oncology, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, 13009 Marseille, France
    Br J Cancer 105:304-11. 2011
    ..We analysed gene expression profiles of ovarian carcinomas to identify a multigene expression model associated with survival after platinum-based therapy...
  7. doi request reprint [Genomics and clinical research for breast cancer]
    Francois Bertucci
    Departement d Oncologie Medicale, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, France
    Med Sci (Paris) 28:14-8. 2012
    ....
  8. pmc Feature extraction and signal processing for nylon DNA microarrays
    F Lopez
    TAGC, INSERM ERM 206, Parc Scientifique de Luminy, 13288 Marseille, France
    BMC Genomics 5:38. 2004
    ..Variation in feature location or in signal integration methodology may be a significant contribution to the observed variance in gene expression levels...
  9. pmc Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Aurore Blesius
    Department of Medicine, Institut Roussy, Villejuif, France
    BMC Cancer 11:72. 2011
    ..We analyzed the outcome of patients with non metastatic locally advanced primary GIST treated with IM within the prospective BFR14 phase III trial...
  10. doi request reprint How different are luminal A and basal breast cancers?
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Marseille, France
    Int J Cancer 124:1338-48. 2009
    ....
  11. ncbi request reprint Gene expression profiling of breast carcinomas using nylon DNA arrays
    Francois Bertucci
    Département d Oncologie Moléculaire, TAGC, Institut Paoli Calmettes IPC, IFR57, 232, bd Ste Marguerite, 13273 Marseille Cedex 9, France
    C R Biol 326:1031-9. 2003
    ..Today, the most accessible approach for academic research teams is that of Nylon DNA arrays with radioactive detection, which in addition allows profiling of small clinical samples...
  12. doi request reprint Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery
    Francois Bertucci
    Institut Paoli Calmettes and UMR599, Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, 232, Bd Sainte Marguerite 13009 Marseille, France
    Future Oncol 4:271-87. 2008
    ..The different techniques currently applied to clinical samples of breast cancer and the most important results obtained are summarized in this review...
  13. doi request reprint [Prognostic classification of breast cancer and gene expression profiling]
    Francois Bertucci
    Centre de Recherche en Cancerologie de Marseille, Departement d Oncologie Medicale, UMR599 Inserm, Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Med Sci (Paris) 24:599-606. 2008
    ..In this review, we present the main results and their potential clinical applications. We also discuss their current limits and future hopes in the therapeutic management of patients...
  14. ncbi request reprint Gene expression profiling of human melanoma cell lines with distinct metastatic potential identifies new progression markers
    Francois Bertucci
    Departments of Medical Oncology, UMR599 Inserm, Institut Paoli Calmettes, Marseille, France
    Anticancer Res 27:3441-9. 2007
    ..Identification of markers associated with melanoma progression is crucial to identify new prognostic and/or therapeutic targets...
  15. ncbi request reprint Gene expression profiling and clinical outcome in breast cancer
    Francois Bertucci
    Centre de Recherche en Cancerologie de Marseille, Oncologie Médicale, Oncologie Moléculaire, UMR599 Inserm Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    OMICS 10:429-43. 2006
    ..In this review we describe current use of DNA microarrays in the prognosis of breast cancer. We also discuss issues that need to be addressed in the near future to allow the method to reach its full potential...
  16. ncbi request reprint [Therapeutic implications of advances in breast cancer biology]
    Francois Bertucci
    Departement d Oncologie Medicale, Département d Oncologie Moléculaire, Institut Paoli Calmettes, IFR57, 13273 Marseille 09
    Rev Prat 54:865-70. 2004
    ..This stratification should make it possible to better tailor the treatment and boost the discovery of new therapeutic targets..
  17. ncbi request reprint Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour
    Francois Bertucci
    Departement d Oncologie Medicale, Institut Paoli Calmettes, 13009 Marseille, France
    Oncol Rep 16:97-101. 2006
    ..Such a approach, far less invasive than surgery and combined with sequencing, will likely help in better tailoring the treatment of advanced GISTs and understanding the mechanisms of resistance and response to imatinib...
  18. ncbi request reprint Proteomics of breast cancer: principles and potential clinical applications
    Francois Bertucci
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, Institut Paoli Calmettes, IPC, and UMR599 INSERM, 13009 Marseille, France
    Mol Cell Proteomics 5:1772-86. 2006
    ....
  19. ncbi request reprint [DNA microarrays for gene expression profiling of breast cancer: principles and prognostic applications]
    F Bertucci
    Departement d Oncologie Medicale, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, 13273 Marseille Cedex 9, France
    Pathol Biol (Paris) 54:49-54. 2006
    ..Recent studies have shown the promising prognostic impact of gene expression profiling in breast cancer by identifying new prognostic subclasses unidentifiable by conventional parameters...
  20. doi request reprint Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer
    Francois Bertucci
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes IPC, Marseille, France
    Breast Cancer Res Treat 127:363-73. 2011
    ..Our predictor refines the prediction of metastasis-free survival after adjuvant anthracycline-based CT and might help tailoring adjuvant CT regimens...
  21. ncbi request reprint [Prognostic value of gene expression profiling using cDNA arrays in lymphomas]
    Francois Bertucci
    Departement d Oncologie Medicale, Institut Paoli Calmettes, IFR57, 232, boulevard de Sainte Marguerite, 13273 Marseille, France
    Bull Cancer 89:661-5. 2002
    ..Recent publications show the potential of DNA arrays to improve the prognostic classification of diffuse large B cell lymphomas and of Hodgkin's lymphoma, by identifying new tumour classes unrecognised by classical factors...
  22. ncbi request reprint Gene expression profiling of inflammatory breast cancer
    Francois Bertucci
    Department of Molecular Oncology, Cancer Research Center of Marseille, Paoli Calmettes Institute, UMR891 Inserm, Marseille, France
    Cancer 116:2783-93. 2010
    ....
  23. doi request reprint How basal are triple-negative breast cancers?
    Francois Bertucci
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, Institut Paoli Calmettes IPC et UMR599 Inserm, Marseille, France
    Int J Cancer 123:236-40. 2008
    ..They also warrant the identification of molecular markers for basal BCs more clinically applicable than gene expression profiles...
  24. pmc Basal breast cancer: a complex and deadly molecular subtype
    F Bertucci
    Departement d Oncologie Medicale, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Marseille, France
    Curr Mol Med 12:96-110. 2012
    ..This review summarizes the current state of knowledge of this aggressive and hard-to-treat subtype of breast cancer...
  25. pmc Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature
    Renaud Sabatier
    Department of Medical Oncology, Institut Paoli Calmettes, 13009 Marseille, France
    BMC Cancer 10:645. 2010
    ..Low-grade extraskeletal osteosarcomas (ESOS) are extremely rare...
  26. ncbi request reprint Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'
    Emmanuelle Charafe-Jauffret
    Département d Oncologie Moléculaire, Institut Paoli Calmettes et U119 INSERM, IFR57, Marseille, France
    J Pathol 202:265-73. 2004
    ..0049 for OS and p < 0.0001 for DFS). In conclusion, an immunophenotypic signature was suggested for IBC. This could help to determine the worst cases, independent of clinical criteria...
  27. pmc Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer
    Jocelyne Jacquemier
    Département d Oncologie Moléculaire Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, UMR891 Inserm, IFR137, 232 Bd sainte Marguerite Marseille, France
    Breast Cancer Res 11:R23. 2009
    ..The aim of this study was to identify the best predictors of success of hormonal therapy...
  28. ncbi request reprint Gene expression profiling defines molecular subtypes of classical Hodgkin's disease
    Elisabeth Devilard
    Department of Pathology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, BP 156, 13273 Marseille Cedex, France
    Oncogene 21:3095-102. 2002
    ..Our results establish a molecular taxonomy of HD correlating with response to therapy and clinical outcome, thereby suggesting the possibility of improving the current prognostic classification...
  29. ncbi request reprint Prognosis and gene expression profiling of 20q13-amplified breast cancers
    Christophe Ginestier
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR599 Inserm, Marseilles, France
    Clin Cancer Res 12:4533-44. 2006
    ..Amplification of chromosomal region 20q13 occurs in breast cancer but remains poorly characterized...
  30. ncbi request reprint Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
    Anthony Goncalves
    Oncologie Médicale, Centre de Recherche en Cancerologie de Marseille, INSERM U891, Institut Paoli Calmettes, 232, boulevard Sainte Marguerite, Marseille 13000, France
    Anticancer Drugs 20:946-52. 2009
    ..The subset of HER2-negative, HR-negative (triple-negative) has a very poor outcome, and innovative therapies are eagerly awaited for these patients...
  31. pmc Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers
    Christophe Ginestier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and Institut National de la Santé et de la Recherche Medical U119, IFR57, Marseille, France
    Am J Pathol 161:1223-33. 2002
    ..Thus, differences extended to clinical prognostic information obtained by the two methods underlining their complementarity and the need for a global molecular analysis of tumors at both the RNA and protein levels...
  32. ncbi request reprint [Inflammatory breast carcinoma: towards molecular characterization?]
    Emmanuelle Charafe-Jauffret
    Département de biopathologie, Institut Paoli Calmettes, Marseille
    Ann Pathol 23:564-9. 2003
    ..It has been shown to be lost in IBC and could control tumor growth, invasion, and angiogenesis. This paper summarizes current knowledge on IBC and describes a new basis for a molecular definition of IBC...
  33. ncbi request reprint Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer
    Christophe Ginestier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and U119 Inserm, IFR57, Marseille, France
    Int J Cancer 107:854-62. 2003
    ..37 (1.21-4.64; p = 0.03). Thus, among the patients who present with tumors of apparent good prognosis, FHIT is an independent prognostic factor that distinguishes a subgroup of patients who could benefit from adjuvant treatment...
  34. pmc Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer
    Emmanuelle Charafe-Jauffret
    Department of Molecular Oncology, Institut Paoli Calmettes UMR891 Institut National de la Sante et de la Recherche Medicale, Universite de la Mediterranee, Marseille Cancer Research Center, Marseille, France
    Clin Cancer Res 16:45-55. 2010
    ..To examine the role of cancer stem cells (CSC) in mediating metastasis in inflammatory breast cancer (IBC) and the association of these cells with patient outcome in this aggressive type of breast cancer...
  35. ncbi request reprint Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers
    Francois Bertucci
    Institut de Cancérologie de Marseille, Département d Oncologie Moléculaire, Institut Paoli Calmettes et Unité Mixte de Recherche 599 Institut National de la Santé et de la Recherche Médicale, Marseilles, France
    Cancer Res 66:4636-44. 2006
    ..Finally, MBCs overexpress a series of genes located on the 12p13 and 6p21 chromosomal regions known to contain pluripotency genes. Our results contribute to a better understanding of MBC and of mammary oncogenesis in general...
  36. ncbi request reprint Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors
    Marine Gilabert
    Oncologie Médicale, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM U891, 232, boulevard Sainte Marguerite, 13009 Marseille, France
    Anticancer Res 31:1079-86. 2011
    ....
  37. ncbi request reprint ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program
    Emmanuelle Charafe-Jauffret
    Authors Affiliations INSERM, U1068, CRCM, Molecular Oncology, Institut Paoli Calmettes, Biopathology, Aix Marseille Univ, UM 105, F 13284, Départements d Oncologie Médicale, Chirugie oncologique, and Radiologie, Institut Paoli Calmettes, Marseille and Plateforme ARN interference PArI, CEA Saclay, Gif sur Yvette, France
    Cancer Res 73:7290-300. 2013
    ..Our work offers a proof of the functional importance of CSCs in breast cancer, and it establishes the reliability of PDXs for use in developing personalized CSC therapies for patients with breast cancer...
  38. pmc Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR1068 Inserm, Institut Paoli Calmettes, Marseille, France
    Haematologica 98:576-83. 2013
    ....
  39. ncbi request reprint Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR599 Institut National de la Santé et de la Recherche Médicale, IFR137, Marseille, France
    Cancer Res 64:8558-65. 2004
    ..These results show the potential of gene expression profiling to contribute to a better understanding of IBC, and to provide new diagnostic and predictive factors for IBC, as well as for potential therapeutic targets...
  40. ncbi request reprint Comprehensive profiling of 8p11-12 amplification in breast cancer
    Véronique Gelsi-Boyer
    Marseilles Cancer Institute, Department of Molecular Oncology, UMR599 Institut National de la Sante et de la Recherche Medicale, France
    Mol Cancer Res 3:655-67. 2005
    ..Finally, we show that 8p11-12 amplification has a pejorative effect on survival in breast cancer...
  41. doi request reprint Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents
    Gais Kadra
    Département de Pharmacologie Moléculaire and U891 INSERM, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, Marseille, France
    Breast Cancer Res Treat 132:1035-47. 2012
    ..Genomic predictors for Tax- and Ixa-sensitivity can be derived from BTCL and may be helpful for better selecting cytotoxic treatment in BC patients...
  42. pmc Kinome expression profiling and prognosis of basal breast cancers
    Renaud Sabatier
    Department of Molecular Oncology, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, 27 Bd Lei Roure, 13009 Marseille, France
    Mol Cancer 10:86. 2011
    ..Kinases are often activated or overexpressed in cancers, and constitute targets for successful therapies. We sought to define a prognostic model of basal BCs based on kinome expression profiling...
  43. doi request reprint High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma
    Jocelyne Jacquemier
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, INSERM UMR89, IFR137, Marseille, France
    Int J Cancer 130:96-104. 2012
    ..0024). In conclusion, high IDO expression is associated with morphological medullary features and has an independent favourable prognostic value in BLBC...
  44. pmc Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature
    Emmanuelle Charafe-Jauffret
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Cancer Res 69:1302-13. 2009
    ....
  45. ncbi request reprint Integrated profiling of basal and luminal breast cancers
    José Adélaïde
    Marseille Cancer Research Center, Department of Molecular Oncology, Institut Paoli Calmettes and UMR599 Institut National de la Santé et de la Recherche Médicale, Marseille, France
    Cancer Res 67:11565-75. 2007
    ..Finally, among 10p candidate oncogenes associated with basal subtype, we validated CDC123/C10orf7 protein as a basal marker...
  46. doi request reprint Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target
    Christophe Ginestier
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, INSERM, Institut Paoli Calmettes, 27 Boulevard Lei Roure, Marseille, France
    Stem Cells 30:1327-37. 2012
    ..The identification of protein GG as a major contributor to CSC maintenance opens promising perspectives for CSC targeted therapy in basal breast cancer...
  47. ncbi request reprint Protein expression profiling identifies subclasses of breast cancer and predicts prognosis
    Jocelyne Jacquemier
    Institut de Cancérologie de Marseille, Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR599 INSERM, 27 Boulevard Lei Roure, Marseille, France
    Cancer Res 65:767-79. 2005
    ..These results show that protein expression profiling may be a clinically useful approach to assess breast cancer heterogeneity and prognosis in stage I, II, or III disease...
  48. pmc Genome profiling of ERBB2-amplified breast cancers
    Fabrice Sircoulomb
    Marseille Cancer Research Center, UMR891 Inserm, Institut Paoli Calmettes, Department of Molecular Oncology, Marseille, France
    BMC Cancer 10:539. 2010
    ..They are associated with a poor prognosis but can benefit from targeted therapy. A better knowledge of these BCs, genomically and biologically heterogeneous, may help understand their behavior and design new therapeutic strategies...
  49. doi request reprint Defining the molecular biology of inflammatory breast cancer
    Emmanuelle Charafe-Jauffret
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR599 INSERM, IFR137, 232 Boulevard Sainte Marguerite, Marseille Cedex 09, France
    Semin Oncol 35:41-50. 2008
    ..The aim of this review is to present and discuss what is known about the biology of this particularly aggressive form of breast cancer and to discuss how this knowledge could improve its management...
  50. doi request reprint Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome
    Bruno Chetaille
    Department of Bio Pathology, Institut Paoli Calmettes and Université de la Mediterranée, Marseille, France
    Blood 113:2765-3775. 2009
    ..The observation of Th1/ antiviral response in EBV(+) cHL tissues provides a basis for novel treatment strategies...
  51. doi request reprint BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer
    Renaud Sabatier
    Department of Molecular Oncology, Centre de Recherche en Cancerologie de Marseille, INSERM UMR891, Marseille, France
    Genes Chromosomes Cancer 49:1143-51. 2010
    ..This observation suggests that BARD1 might be a BC susceptibility gene that follows the Knudson rule. Identification of BARD1 deletion could have clinical applications including screening for hereditary forms. © 2010 Wiley-Liss, Inc...
  52. doi request reprint Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis
    Pascal Finetti
    UMR599 Inserm, Institut Paoli Calmettes, Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    Cancer Res 68:767-76. 2008
    ..The identification of luminal A cases of poor prognosis should help select appropriate treatment, whereas the identification of a relevant kinase set provides potential targets...
  53. pmc Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes
    Anthony Goncalves
    Department of Molecular Pharmacology, Marseille Research Cancer Center, Marseille, France
    Mol Cell Proteomics 7:1420-33. 2008
    ..Our study shows the potential of integrated genomics and proteomics profiling to improve molecular knowledge of complex tumor phenotypes and identify biomarkers with valuable diagnostic or prognostic values...
  54. pmc FGFR1 and WT1 are markers of human prostate cancer progression
    Elizabeth Devilard
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm et Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:272. 2006
    ..Androgen-independent prostate adenocarcinomas are responsible for about 6% of overall cancer deaths in men...
  55. pmc Gene expression profiling of solitary fibrous tumors
    Francois Bertucci
    Département d Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille CRCM, Institut Paoli Calmettes IPC, UMR1068 Inserm, Marseille, France
    PLoS ONE 8:e64497. 2013
    ..They raise several clinical problems. Differential diagnosis may be difficult, prognosis is poorly apprehended by histoclinical features, and no effective therapy exists for advanced stages...
  56. doi request reprint [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives]
    Anthony Goncalves
    Institut Paoli Calmettes, Oncologie Médicale, 232, boulevard Sainte Marguerite, 13009 Marseille, France
    Bull Cancer 100:453-64. 2013
    ..Recent data indicate that TNBC represent a heterogeneous entity composed of multiple and distinct molecular subtypes, which should deserve specific targeted therapeutics...
  57. pmc Are there candidates for high-dose chemotherapy in ovarian carcinoma?
    Renaud Sabatier
    Department of Medical Oncology, Institut Paoli Calmettes, 232 Bd Ste Marguerite, Marseille 13273, France
    J Exp Clin Cancer Res 31:87. 2012
    ..Prognosis of advanced ovarian carcinomas (AOC) remains poor with a 5-year survival of 30%. Benefit from high-dose chemotherapy (HDC) in this disease has not been demonstrated to date...
  58. ncbi request reprint DNA arrays in clinical oncology: promises and challenges
    Francois Bertucci
    Department of Molecular Oncology FB, DB, Institut Paoli Calmettes, Marseille, France
    Lab Invest 83:305-16. 2003
    ..Finally, we discuss issues that must be resolved in the near future to allow DNA arrays to translate into benefits for cancer patients...
  59. ncbi request reprint Breast cancer revisited using DNA array-based gene expression profiling
    Francois Bertucci
    Department of Molecular Oncology, Institut Paoli Calmettes, Marseille, France
    Int J Cancer 103:565-71. 2003
    ..This review presents recent applications of DNA arrays in breast cancer research and discusses some issues to address in the near future to allow the technology to reach its full potential...
  60. pmc Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin
    Azza Ben Hamida
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm, Marseille, France
    BMC Cancer 8:28. 2008
    ..The aim of this study was to determine the distribution of molecular subtypes in IBC and identify factors that may explain the poor prognosis of IBC...
  61. doi request reprint Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis
    Anthony Goncalves
    Département d Oncologie Médicale and U891 INSERM, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, 232 Bd Ste Marguerite, 13009 Marseille, France
    Breast Cancer Res Treat 127:273-81. 2011
    ..These data demonstrate overexpression of PARP1 in a large number of breast cancers and support the development of PARP inhibitors in basal subtype, but also potentially in other breast cancer subtypes...
  62. ncbi request reprint Moesin expression is a marker of basal breast carcinomas
    Emmanuelle Charafe-Jauffret
    Laboratory of Molecular Oncology, Marseille Cancer Research Institute, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    Int J Cancer 121:1779-85. 2007
    ..014). In multivariate analysis, Moesin expression was nearly an independent prognostic marker of poor outcome as shown by Cox proportional hazard model in patients without lymph node metastasis (p = 0.052, HR = 2.38, CI 95[0.99-5.69])...
  63. pmc A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment
    Anthony Goncalves
    Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France
    BMC Cancer 8:169. 2008
    ..Mutational status of KRAS and EGFR, and EGFR copy number are potential determinants of cetuximab activity...
  64. ncbi request reprint Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and U119 Inserm, IFR57, Marseille, France
    Oncogene 23:1377-91. 2004
    ..These results suggest that microarrays may provide means to improve the classification of CRC, provide new potential targets against carcinogenesis and new diagnostic and/or prognostic markers and therapeutic targets...
  65. ncbi request reprint [Tissue microarrays a powerful tool in transfer and quality control in oncology]
    Jocelyne Jacquemier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, 232, Bd de Sainte Marguerite, 13273 Marseille Cedex 9
    Bull Cancer 90:31-8. 2003
    ..This article provides a short review of this technology, and points out several aspects of the TMA construction and its applications for clinical research...
  66. ncbi request reprint Gene expression profiles of poor-prognosis primary breast cancer correlate with survival
    Francois Bertucci
    Département d Oncologie Moléculaire TAGC, U 119 INSERM, Marseille, France
    Hum Mol Genet 11:863-72. 2002
    ..Furthermore, the characterization of discriminator genes might accelerate the development of new specific and alternative therapies, allowing more rationally tailored treatments that are potentially more efficient and less toxic...
  67. ncbi request reprint Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling
    Norbert Vey
    Department of Molecular Oncology, Institut Paoli Calmettes UMR599 Inserm, IFR137, Marseille Cancer Institute, Marseille, France
    Oncogene 23:9381-91. 2004
    ..Our results demonstrate the transcriptional heterogeneity of NC-AMLs, and suggest the existence of 'translocation-like' NC-AMLs and of a gene expression signature that may predict response to chemotherapy...
  68. ncbi request reprint Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets
    Emilie Mamessier
    Centre de Recherche en Cancerologie de Marseille, INSERM Unité Mixte de Recherche 1068, 13009 Marseille, France
    J Immunol 190:2424-36. 2013
    ..The identification of NK cell subsets endowed with particular functional capabilities might help monitor residual antitumor NK cell-mediated responses in breast cancer patients...
  69. pmc 8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer
    Francois Bertucci
    Centre de Recherche en Cancerologie de Marseille, Department of Molecular Oncology, Institut Paoli Calmettes, Marseille, France
    PLoS ONE 7:e37943. 2012
    ..We investigated here two 8q24 breast and colon cancer risk alleles in the close vicinity of the MYC gene for their role in the occurrence of distant metastases...
  70. ncbi request reprint [Small but high throughput: how "tissue-microarrays" became a favorite tool for pathologists and scientists]
    Jocelyne Jacquemier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, 232 Bd de Sainte Marguerite, 13273 Marseille Cedex 9, France
    Ann Pathol 23:623-32. 2003
    ..This Article provides a short review of this technology, and points out several aspects of the TMA construction and its applications for clinical research...
  71. doi request reprint A gene expression signature identifies two prognostic subgroups of basal breast cancer
    Renaud Sabatier
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Breast Cancer Res Treat 126:407-20. 2011
    ..This signature could help define the prognosis, adapt the systemic treatment, and identify new therapeutic targets...
  72. pmc CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines
    Gwladys Zabouo
    Institut Paoli Calmettes, Centre de Ressources Biologiques en Oncologie, Centre de Thérapie Cellulaire et Génique, Marseille, France
    Breast Cancer Res 11:R1. 2009
    ..Studies of CD146 expression and function in breast cancer remain scarce except for a report concluding that CD146 could act as a tumor suppressor in breast carcinogenesis...
  73. doi request reprint Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome
    Renaud Sabatier
    Molecular Oncology Department, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Eur J Cancer 47:1537-45. 2011
    ..Nevertheless TNBC are heterogeneous in terms of pathological, biological and prognostic behaviours. We explored clinical and pathological factors correlated with outcome in this phenotype...
  74. pmc Retinoid signaling regulates breast cancer stem cell differentiation
    Christophe Ginestier
    Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm Institut Paoli Calmettes, Marseilles, France
    Cell Cycle 8:3297-302. 2009
    ..These pathways regulate breast CSCs biology and their inhibition may provide novel therapeutic approaches to target breast CSCs...
  75. doi request reprint [Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers]
    Marine Gilabert
    Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, U891 Inserm, Oncologie Médicale, Marseille, France
    Bull Cancer 97:321-39. 2010
    ..The current techniques applied to clinical samples of breast cancer and the most important results obtained are summarized in this review...
  76. ncbi request reprint Prognosis of breast cancer and gene expression profiling using DNA arrays
    Francois Bertucci
    Département d Oncologie Moléculaire, TAGC, Institut Paoli Calmettes IPC, IFR57, Marseille, France
    Ann N Y Acad Sci 975:217-31. 2002
    ..We also showed that nylon DNA arrays with radioactive detection are associated with excellent sensitivity, an advantage in clinical situations where the amount of available material is limited...
  77. ncbi request reprint Gene expression profiling and its utility in prediction of local relapse after breast-conserving therapy in early breast cancer
    Renaud Sabatier
    Department of Molecular Oncology, Marseille Cancer Research Center, Paoli Calmettes Institute, UMR891 Inserm, Marseille, France
    Cancer Genomics Proteomics 8:199-209. 2011
    ..Local relapse (LR) after breast-conserving therapy (BCT) is not accurately predicted by histological/clinical factors. Gene expression profiling was used here to discover LR-associated transcriptional alterations...
  78. ncbi request reprint Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas
    Olivier Ramuz
    Department of Pathology, Institut Paoli Calmettes, BP 156, 13273 Marseille Cedex 9, France
    Int J Oncol 26:151-7. 2005
    ..Our data suggest that TCL1A immunodetection is an independent marker of adverse outcome that could be used in routine settings for the management of DLCL patients...
  79. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
    ..We searched for prognostic and predictive markers for docetaxel's benefit...
  80. ncbi request reprint [Gene expression profiling using cDNA arrays and prognosis of breast cancer]
    Francois Bertucci
    Département d oncologie moléculaire TAGC technologies avancées pour le génome et la clinique, Institut Paoli Calmettes, IFR57, 27, bd Le Roure, 13009 Marseille, France
    Bull Cancer 89:571-4. 2002
    ..Results of the pioneering studies are promising: expression profiling of breast tumours using cDNA arrays seems able to identify new prognostic sub-classes unidentifiable using conventional parameters...
  81. ncbi request reprint Characterization of Hodgkin's lymphoma-like undifferentiated carcinoma of the nasopharyngeal type as a particular UCNT subtype mimicking Hodgkin's lymphoma
    Emmanuelle Charafe-Jauffret
    Department of Pathology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, BP 156, F 13273 Marseille cedex 9, France
    Int J Oncol 23:97-103. 2003
    ..These results show that UCNT morphologically resembling HL share also some specific phenotypical and molecular features with HL, and might deserve to be isolated as a particular UCNT subtype...
  82. pmc Loss, mutation and deregulation of L3MBTL4 in breast cancers
    Lynda Addou-Klouche
    Marseille Cancer Research Center, Department of Molecular Oncology, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Mol Cancer 9:213. 2010
    ..Many alterations are involved in mammary oncogenesis, including amplifications of oncogenes and losses of tumor suppressor genes (TSG). Losses may affect almost all chromosome arms and many TSGs remain to be identified...
  83. doi request reprint Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations
    Ying Yang
    INSERM U891, Centre de Recherche en Cancerologie de Marseille, Laboratoire de Signalisation, Hématopoïèse et Mécanisme de l Oncogenèse, Centre de Référence des Mastocytoses CEREMAST Institut Paoli Calmettes, 27 Boulevard Lei Roure, Marseille, France
    Blood 116:1114-23. 2010
    ..Overall, our study implied different pathogenesis of pediatric versus adult mastocytosis, which might explain their diverse phenotypes...
  84. doi request reprint [Targeted chemotherapy for breast cancer: patients perception of the use of tumor gene profiling approaches to better adapt treatments]
    Isabelle Pellegrini
    Inserm UMR912, IRD, Marseille, France
    Med Sci (Paris) 28:24-7. 2012
    ..This will ensure that those who agree to their tumor gene analysis have realistic expectations and sound deductions of the final result disclosure process...
  85. pmc Primary leiomyosarcoma of the seminal vesicle: case report and review of the literature
    Cécile Cauvin
    Department of Radiotherapy, Institut Paoli Calmettes, 27 Bd Lei Roure, 13009, Marseille, France
    BMC Cancer 11:323. 2011
    ..Primary leiomyosarcoma of the seminal vesicle is exceedingly rare...
  86. ncbi request reprint [Towards an integrated cellular and molecular: definition of breast cancers]
    Emmanuelle Charafe-Jauffret
    UMR 599 Inserm, Institut Paoli Calmettes, Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancérologie de Marseille et Université de la Méditerranée, 27, boulevard Lei Roure, 13009 Marseille, France
    Med Sci (Paris) 23:626-32. 2007
    ..These combined studies allow a new integrated cellular and molecular definition of breast cancers and a conceptual basis that will help the management of the disease...
  87. pmc ZNF703 gene amplification at 8p12 specifies luminal B breast cancer
    Fabrice Sircoulomb
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, INSERM, U891, Institut Paoli Calmettes, Marseille, France
    EMBO Mol Med 3:153-66. 2011
    ..Moreover, we show that ZNF703 is implicated in the regulation of ER and E2F1 transcription factor. These findings point out the prominent role of ZNF703 in transcription modulation, stem cell regulation and luminal B oncogenesis...
  88. pmc Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review
    Simon G Launay
    Department of Medical Oncology, Institut Paoli Calmettes, 232 Bd Ste Marguerite, Marseille, 13009, France
    BMC Cancer 11:423. 2011
    ..They are characterized by slow growth and long history with frequent local relapses, and sometimes metastases. While chemotherapy is not efficient, imatinib has shown antitumor activity...
  89. ncbi request reprint Basal and luminal breast cancers: basic or luminous? (review)
    Daniel Birnbaum
    Laboratoire d Oncologie Moleculaire, Institut Paoli Calmettes and UMR599 INSERM, 13009 Marseille, France
    Int J Oncol 25:249-58. 2004
    ..The combined effects of these progresses on our understanding of breast cancer biology should have major consequences on the way this disease is managed...
  90. doi request reprint A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia
    Hugues de Lavallade
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, Institut Paoli Calmettes and Inserm UMR891, Marseille, France
    Leuk Res 34:254-7. 2010
    ..These findings may prove useful for identifying at the time of diagnosis a subset of CP-CML patients who are likely to be resistant to imatinib and require an alternative treatment...
  91. doi request reprint Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition
    Emilie Mamessier
    Centre de Recherche en Cancerologie de Marseille, Genova, Italy
    Cancer Res 71:6621-32. 2011
    ..These results emphasize the role of NK cells in breast tumor clearance and underlie the importance of devising future therapy aiming at enhancing NK cell-mediated recognition in parallel with the prevention of the tumor-editing process...
  92. ncbi request reprint Gene expression profiling and prediction of clinical outcome in ovarian cancer
    Renaud Sabatier
    Centre de Recherche en Cancérologie de Marseille CRCM, Département d Oncologie Moléculaire, UMR891 Inserm, Institut Paoli Calmettes IPC, IFR137 Marseille, France
    Crit Rev Oncol Hematol 72:98-109. 2009
    ..In this review, we describe recent applications of DNA microarrays in ovarian cancer research and discuss some issues to address in the near future to allow the technology to reach its full potential in clinical practice...
  93. pmc Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
    Emilie Mamessier
    Centre de Recherche en Cancerologie de Marseille, INSERM UMR U891, Marseille, France
    J Clin Invest 121:3609-22. 2011
    ..This highlights the importance of developing future therapies able to restore NK cell cytotoxicity to limit/prevent tumor escape from antitumor immunity...
  94. ncbi request reprint [Proteic profiling SELDI-TOF and breast cancer: clinical potential applications]
    Anthony Goncalves
    Centre de Recherche en Cancerologie de Marseille, Département de Pharmacologie Moléculaire, Institut Paoli Calmettes IPC et Inserm UMR 599, Marseille, France
    Med Sci (Paris) 23:23-6. 2007
    ..Proteomic technologies, including SELDI-TOF (surface enhanced laser desorption/ionization-time of flight) mass spectrometry, are emerging tools that may contribute to better reach these key objectives...
  95. pmc Distant metastasis: not out of reach any more
    Francois Bertucci
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR 891 INSERM, Institut Paoli Calmettes, Marseille, France
    J Biol 8:28. 2009
    ..Two recent papers in BMC Medicine and BMC Cancer have established new operational expression signatures containing a limited number of genes involved in angiogenesis or cell proliferation...
  96. ncbi request reprint Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study
    F Viret
    Medical Oncology Department, Institut Paoli Calmettes, Marseille, France
    Bone Marrow Transplant 30:879-84. 2002
    ..This pilot study shows that dose-dense chemotherapy with paclitaxel and carboplatin is associated with low toxicity and may improve the outcome of patients with poor prognosis ovarian cancer...
  97. ncbi request reprint Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experience
    Patrice Viens
    Department of Medical Oncology, Paoli Calmettes Institute, Marseille Cancer Research Center, UMR891 Inserm, IFR137, Marseille, France
    Cancer 116:2829-36. 2010
    ....
  98. ncbi request reprint Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene
    Cornel Popovici
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, Marseille, France
    Genes Chromosomes Cancer 35:204-18. 2002
    ..Additional experiments using comparative genomic hybridization provided further information on the genomic context in which the t(3;20)(p14;p11) reciprocal translocation was found...
  99. doi request reprint Clinical application of proteomics in breast cancer: state of the art and perspectives
    Anthony Goncalves
    Centre de Recherche en Cancerologie de Marseille, Département de Pharmacologie Moléculaire, Institut Paoli Calmettes et UMR599 Inserm, Marseille, France
    Med Princ Pract 20:4-18. 2011
    ..Despite their current limits, these pioneering techniques are promising. The most important results as well as the current limitations and perspectives are summarized and discussed...
  100. ncbi request reprint Lung cancer in elderly patients: a retrospective analysis of practice in a single institution
    Anne Madroszyk-Flandin
    Department of Medicine, Institut Paoli Calmettes, 232 Bd Sainte Marguerite, 13273 Marseille Cedex 9, France
    Crit Rev Oncol Hematol 64:43-8. 2007
    ..6, ND) and 5.7 months (95%; 4.2-9.6) for stage IIIB and IV, respectively. Toxicities were judged acceptable with 19 hospitalizations after chemotherapy, for 16 patients who represent 34.8% of patients who received chemotherapy...
  101. ncbi request reprint [Genetic factors and colorectal cancers development: therapeutic impact]
    Sylviane Olschwang
    Institut Paoli Calmettes, Centre Regional de Lutte Contre le Cancer, Provence Alpes Cote d Azur, INSERM UMR 599, Marseille, France
    Med Sci (Paris) 22:45-9. 2006
    ..Real time RT-PCR and immunohistochemical analyses will be performed on selected genes. Finally, biological mechanisms will be investigated to look for new therapeutic targets...